Accretion Pharmaceuticals Limited IPO
Table of Contents
Disclaimer
The stock market is subject to significant volatility and inherent risks. Investing in stocks involves potential losses and is not guaranteed to generate profits. Prices of stocks can fluctuate unpredictably. We do not give you any buy/sell tips. This article is for Educational purposes only.
Accretion Pharmaceuticals Limited IPO: Key Details, GMP, and Allotment Insights
The Accretion Pharmaceuticals IPO is a bookbuilding issue valued at ₹29.75 crores, with a fresh issue of 29.46 lakh shares.
The Accretion Pharmaceuticals IPO opened for subscription on May 14, 2025, and will close on May 16, 2025. The allotment for the IPO is expected to be finalized on Monday, May 19, 2025, and shares will list on the NSE SME platform on Wednesday, May 21, 2025.
The price band for the Accretion Pharmaceuticals IPO is set between ₹96 to ₹101 per share. The minimum lot size for an application is 1,200 shares, requiring a minimum investment of ₹1,15,200 for retail investors. To avoid oversubscription, it is recommended that investors bid at the cutoff price, which is approximately ₹1,21,200. For HNI investors, the minimum lot size is 2 lots (2,400 shares), amounting to ₹2,42,400.
Price Band and Investment Details
- Price Band: ₹96 to ₹101 per share
- Minimum Lot Size: 1,200 shares
- Retail Investment: Starting at ₹1,21,200 (1 Lots)
- HNI Investment: ₹2,42,400 (2 Lots or 2,400 shares)

Accretion Pharmaceuticals IPO Details
IPO Date | May 14, 2025 to May 16, 2025 |
Listing Date | May 21 2025 |
Face Value | ₹10 per share |
Issue Price Band | ₹96 to ₹101 per share |
Lot Size | 1,200 Shares |
Total Issue Size | 29,46,000 shares (aggregating up to ₹29.75 Cr) |
Fresh Issue | 29,46,000 shares (aggregating up to ₹29.75 Cr) |
Issue Type | Bookbuilding IPO |
Listing At | NSE SME |
Share Holding Pre Issue | 81,70,000 shares |
Share Holding Post Issue | 1,11,16,000 shares |
Market Maker Portion | 1,47,600 shares Gretex Share Broking Private Limited |
Accretion Pharmaceuticals IPO Timeline
IPO Open Date | Wed, May 14, 2025 |
IPO Close Date | Fri, May 16, 2025 |
Tentative Allotment | Mon, May 19, 2025 |
Initiation of Refunds | Tue, May 20, 2025 |
Credit of Shares to Demat | Tue, May 20, 2025 |
Tentative Listing Date | Wed, May 21, 2025 |
Cut-off time for UPI mandate confirmation | 5 PM on May 16, 2025 |

Accretion Pharmaceuticals IPO Lot Size
Application | Lots | Shares | Amount |
---|---|---|---|
Retail (Min) | 1 | 1200 | ₹1,21,200 |
Retail (Max) | 1 | 1200 | ₹1,21,200 |
HNI (Min) | 2 | 2,400 | ₹2,42,400 |
Lot Size Calculator |
Accretion Pharmaceuticals IPO Reservation
Investor Category | Shares Offered |
---|---|
QIB Shares Offered | Not more than 50.00% of the Net Issue |
Retail Shares Offered | Not less than 35.00% of the Net Issue |
NII (HNI) Shares Offered | Not more than 15.00% of the Net Issue |
Accretion Pharmaceuticals Limited Financial Information
Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
Assets | 39.99 | 27.05 | 20.58 | 17.74 |
Revenue | 35.75 | 33.94 | 29.53 | 22.58 |
Profit After Tax | 5.24 | 3.88 | 0.10 | 0.08 |
Net Worth | 13.58 | 5.35 | 3.84 | 3.08 |
Reserves and Surplus | 5.41 | 1.35 | 0.00 | 0.00 |
Total Borrowing | 13.79 | 13.48 | 8.47 | 7.61 |
Amount in ₹ Crore |

Conclusion
Maximising Opportunities with Accretion Pharmaceuticals Limited IPO
Accretion Pharmaceuticals Limited IPO offers an exciting investment opportunity, seeking to raise ₹29.75 crore through the issuance of 29.46 lakh fresh equity shares. With a price band set between ₹96 to ₹101 per share, the IPO presents an attractive proposition for both retail investors and high-net-worth individuals (HNIs).
The IPO subscription period opened on May 14, 2025, and will close on May 16, 2025. The allotment of shares is expected to be finalized by May 19, 2025, with shares to be credited to demat accounts on May 20, 2025. The listing of shares is tentatively scheduled for May 21, 2025 on the NSE SME platform.
For retail investors, the minimum lot size is 1,200 shares, requiring an investment of ₹1,21,200. For HNIs, the minimum investment is ₹2,42,400, which corresponds to two lots (2,400 shares). This IPO offers an opportunity to participate in the pharmaceutical sector, a rapidly growing industry with significant potential.
Accretion Pharmaceuticals, established in 2012, is based in Gujarat and specializes in manufacturing a wide range of pharmaceutical products, including tablets, capsules, oral liquids, and external preparations. The company is also involved in contract manufacturing services for third-party marketers, showcasing its diverse business model.
The proceeds from the IPO will be used for capital expenditure, including the purchase of new equipment, upgrading existing manufacturing facilities, debt repayment, and working capital needs. With a solid track record and ambitious growth plans, Accretion Pharmaceuticals presents a promising investment opportunity in the Indian pharmaceutical market.